Inclusion Criteria: • Availability
of tumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour
type specific inclusion criteria) • At least one measurable
lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate
bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 %
of the lower limit
of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor
type specific exclusion criteria